PLEASANTON, Calif. and PARIS, Nov. 6, 2023 /PRNewswire/ -- OWKIN and 10x Genomics, Inc. (Nasdaq: TXG), announce they have entered into an agreement to add 10x Genomics spatial omics and single-cell technologies to the ambitious MOSAIC project, which has already garnered attention for its pioneering work in tumor analysis for therapeutic discovery..

PLEASANTON，CA和PARIS，2023年11月6日/PRNewswire/-OWKIN和10x Genomics，Inc。（纳斯达克股票代码：TXG），宣布他们已达成协议，加入10x Genomics spatial omics和单细胞技术雄心勃勃的MOSAIC项目，该项目因其在肿瘤分析治疗发现方面的开创性工作而备受关注。。

Unveiled in June 2023, MOSAIC is a landmark $50 million project that leverages spatial omics technologies to map tumor structures at single-cell resolution, encompassing an astounding 7,000 tumor samples—100 times larger than any comparable dataset. With the addition of 10x Genomics' state-of-the-art Visium technology for spatial transcriptomics and leading Chromium portfolio for single-cell analysis, MOSAIC is poised to unlock transformative discoveries in the battle against cancer, unveiling unprecedented insights into tumor and immune cell interactions..

MOSAIC于2023年6月推出，是一个具有里程碑意义的5000万美元项目，利用空间组学技术以单细胞分辨率绘制肿瘤结构图，涵盖了惊人的7000个肿瘤样本-比任何可比较的数据集大100倍。随着10x Genomics最先进的空间转录组学Visium技术和领先的单细胞分析铬组合的加入，MOSAIC有望解开与癌症作斗争的变革性发现，揭示对肿瘤和免疫的前所未有的见解细胞相互作用。。

'Spatial omics, combined with deep multimodal patient profiling, will revolutionize our understanding of cancer biology. I am really excited that the MOSAIC study will use the 10x Visium and Chromium platforms to generate spatial and single-cell transcriptomics for thousands of cancer patients. Powered by Owkin's unique AI, and the collective expertise of our partners, such data is a unique asset to mine for novel targets, understanding patient response and resistance to current treatments and ultimately to develop new therapies for cancer patients,' said Eric Durand, SVP Data Science at Owkin..

'空间组学与深度多模式患者分析相结合，将彻底改变我们对癌症生物学的理解。我非常高兴MOSAIC研究将使用10x Visium和Chromium平台为数千名癌症患者生成空间和单细胞转录组学。在Owkin独特的人工智能和我们合作伙伴的集体专业知识的支持下，这些数据是挖掘新目标，了解患者对当前治疗的反应和抵抗力以及最终为癌症患者开发新疗法的独特资产，“Eric Durand说，奥金的SVP数据科学。。

Jim Wilbur, Chief Commercial Officer at 10x Genomics, said, 'We're thrilled to have our leading technologies take on such an important, enabling role in the MOSAIC study. With the addition of 10x, the distinguished team of MOSAIC researchers will have access to world-class single cell and spatial tools.

10x Genomics的首席商业官Jim Wilbur说：“我们很高兴我们的领先技术在MOSAIC研究中发挥如此重要的有利作用。随着10倍的增加，杰出的马赛克研究团队将可以使用世界级的单细胞和空间工具。

We're confident our technology platforms will enable the exceptional quality data required to fulfill the project's ambitious mission. The ability to glean single-cell and spatial information from thousands of patient samples and analyze them at scale with Owkin's powerful AI technology will have a profound impact that has the potential to transform the future of cancer care.'  .

我们相信，我们的技术平台将能够实现项目雄心勃勃的使命所需的卓越质量数据。利用Owkin强大的人工智能技术从数千个患者样本中收集单细胞和空间信息并进行大规模分析的能力将产生深远的影响，有可能改变癌症治疗的未来  .

About MOSAICMOSAIC is a global initiative uniting top academic centers and industry partners to create the world's largest spatial omics and multimodal dataset in oncology. Through the convergence of large-scale spatial omics data and AI, MOSAIC will power the next revolution in cancer research, bringing about the identification of novel treatment response and resistance mechanisms, new patient subtypes, and biomarkers for prognostics and diagnostic patient stratification..

关于马赛克是一项全球倡议，联合顶级学术中心和行业合作伙伴创建世界上最大的空间组学和肿瘤学多模式数据集。通过大规模空间组学数据和人工智能的融合，MOSAIC将为癌症研究的下一次革命提供动力，从而确定新的治疗反应和耐药机制，新的患者亚型，以及用于预后和诊断患者分层的生物标志物。。

About Owkin Owkin is a TechBio company that combines the best of human and artificial intelligence to ensure every patient gets the right treatment. By understanding complex biology through AI, we identify new treatments, de-risk and accelerate clinical trials and develop AI diagnostics. Owkin uses privacy-enhancing federation to access up-to-date multimodal patient data that unlocks AI's potential to power precision medicine.

关于Owkin Owkin是一家TechBio公司，结合了人类和人工智能的最佳状态，确保每位患者都能得到正确的治疗。通过AI了解复杂的生物学，我们确定新的治疗方法，降低风险并加速临床试验并开发AI诊断。Owkin使用隐私增强联合会访问最新的多模式患者数据，从而释放AI为精准医学提供动力的潜力。

We merge wet lab experiments with advanced AI techniques to create a powerful feedback loop for accelerated discovery and innovation. Owkin founded MOSAIC, the world's largest multi-omics atlas for cancer research. Owkin has raised over $300 million through investments from leading biopharma companies (Sanofi and BMS) and venture funds (Fidelity, GV and BPI, among others).

我们将湿实验室实验与先进的人工智能技术相结合，为加速发现和创新创造强大的反馈回路。Owkin创立了MOSAIC，这是世界上最大的癌症研究多组学地图集。Owkin通过领先的生物制药公司（赛诺菲和BMS）和风险基金（Fidelity，GV和BPI等）的投资筹集了超过3亿美元。

ContactsMedia: [email protected]

ContactsMedia:[电子邮件保护]

About 10x Genomics10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health. Our integrated solutions include instruments, consumables and software for single cell and spatial biology, which help academic and translational researchers and biopharmaceutical companies understand biological systems at a resolution and scale that matches the complexity of biology.

大约10x Genomics10x Genomics是一家生命科学技术公司，致力于加速生物学掌握和促进人类健康。我们的综合解决方案包括用于单细胞和空间生物学的仪器，消耗品和软件，这有助于学术和转化研究人员以及生物制药公司以与生物学复杂性相匹配的分辨率和规模理解生物系统。

Our products are behind breakthroughs in oncology, immunology, neuroscience and more, fueling powerful discoveries that are transforming the world's understanding of health and disease. To learn more, visit 10xgenomics.com or connect with us on LinkedIn or X (Twitter)..

我们的产品落后于肿瘤学，免疫学，神经科学等领域的突破，推动了正在改变世界对健康和疾病认识的强大发现。要了解更多信息，请访问10xgenomics.com或通过LinkedIn或X（Twitter）与我们联系。。

Disclosure Information

披露信息

10x Genomics uses filings with the Securities and Exchange Commission, our website (www.10xgenomics.com), press releases, public conference calls, public webcasts and our social media accounts as means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD..

10x Genomics使用美国证券交易委员会，我们的网站（www.10xgenomics.com），新闻稿，公共电话会议，公共网络广播和我们的社交媒体帐户提交的文件，作为披露材料非公开信息和遵守我们在FD法规下的披露义务的手段。。

Contacts Investors: [email protected]Media: [email protected]

联系投资者：[电子邮件保护]媒体：[电子邮件保护]

SOURCE 10x Genomics, Inc

来源10x Genomics，Inc